3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Zimri Hinshaw of BUCHA BIO, Kelly Klein of Easter Seals of Greater Houston, ad John Mooz of Hines. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from esports to biomaterials — recently making headlines in Houston innovation.

Zimri Hinshaw, CEO of BUCHA BIO

Zimri T. Hinshaw, CEO of BUCHA BIO, joins the Houston Innovators Podcast to discuss how he's planning to scale his biomaterials startup to reduce plastic waste. Photo courtesy of BUCHA BIO

After raising a seed round of funding, BUCHA BIO is gearing up to move into its new facility. The biomaterials company was founded in New York City in 2020, but CEO Zimri T. Hinshaw shares how he started looking for a new headquarters for the company — one that was more affordable, had a solid talent pool, and offered a better quality of life for employees. He narrowed it down from over 20 cities to two — San Diego and Houston — before ultimately deciding on the Bayou City.

Since officially relocating, Hinshaw says he's fully committed to the city's innovation ecosystem. BUCHA BIO has a presence at the University of Houston, Greentown Labs, and the East End Maker Hub — where the startup is building out a new space to fit the growing team.

"By the end of this month, our laboratories will be up and running, we'll have office space adjacent, as well as chemical storage," Hinshaw says on the Houston Innovators Podcast. Listen to the episode and read more.

Kelly Klein, development director of Easter Seals Greater Houston

A nonprofit organization has rolled out an esports platform and event to raise awareness and funding for those with disabilities. Photo via Easter Seals

For many video games is getaway from reality, but for those with disabilities — thanks to a nonprofit organization —gaming can mean a lot more. On Saturday Dec. 3 — International Day of Persons with Disabilities — from 1 to 9 pm, Easter Seals Greater Houston will be joining forces with ES Gaming for the inaugural Game4Access Streamathon.

Gaming helps enhance cognitive skills, motor skills, improve mental well-being, and can help reduce feelings of social isolation due to the interactive nature of playing with others.

“This is really a unique way for (people) to form a community without having to leave their house, and being part of an inclusive environment,” says Kelly Klein, development director of Easter Seals Greater Houston. ”The adaptive equipment and specialized technology just does so many miraculous things for people with disabilities on so many levels — not just gaming. With gaming, it is an entrance into a whole new world.” Read more.

John Mooz, senior managing director at Hines

Levit Green has announced its latest to-be tenant. Photo courtesy

Levit Green, a 53-acre mixed-use life science district next to the Texas Medical Center and expected to deliver this year, has leased approximately 10,000 square feet of commercial lab and office space to Sino Biological Inc. The Bejing-based company is an international reagent supplier and service provider. Houston-based real estate investor, development, and property manager Hines announced the new lease in partnership with 2ML Real Estate Interests and Harrison Street.

“Levit Green was meticulously designed to provide best-in-class life science space that can accommodate a multitude of uses. Welcoming Sino Biological is a testament to the market need for sophisticated, flexible space that allows diversified firms to perform a variety of research,” says John Mooz, senior managing director at Hines, in a press release. “Sino is an excellent addition to the district’s growing life science ecosystem, and we look forward to supporting their continued growth and success.” Read more.Read more.

From Your Site Articles
Hines is doubling down on life science real estate development, the firm recently reported. Image courtesy of Hines

Houston-based real estate giant bets on growing life science sector

shifting focus

An international real estate firm announced recently that it would prioritizing investing in life science industry opportunities when it comes to commercial real estate development.

Houston-based Hines reported that the pandemic has heightened the demand for life science real estate, and the firm explained in a news release that it will be delivering purpose-built life science facilities in growing markets that feature state-of-the-art, operator-driven design and amenities.

“The life sciences sector is experiencing an era of unprecedented growth driven by a rise in both public and private funding combined with a post-pandemic sense of urgency and market opportunity,” says David Steinbach, global CIO at Hines, in the release. “As this industry surges, it is pivotal that developers keep pace by delivering spaces that are as innovative as the tenants occupying them. Hines is dedicated to delivering purpose-built facilities that meet the physical, functional and technological needs of the occupiers.”

When it comes to design, Hines will focus on structural specification and the balance of lab and office space, providing tenants — who are all looking or different types of spaces and amenities — with flexibility and modular design.

ESG is something Hines is reportedly considering top of mind for developers, investors and occupiers, with plans to build efficient assets, source from sustainable energy, and provide low-carbon emission options.

Hines has already announced this type of facility currently in construction in Houston. Levit Green is a five-story, 270,000-square-foot Phase I lab building that has flexible Class AA quality labs key features required by top life science tenants. According to Hines, Levit Green's building features will include emergency power sources, 33-foot structural bay depths, allowing for an ideal 11-foot lab module, and floorplates more than 55,000 square feet will also enable research and office teams to create efficient configurations that enable teamwork and collaboration.

“Our carefully built team of national life science leasing, design and capital experts has put a tremendous amount of thought and effort into Levit Green’s planning and design. We are confident that our team will deliver one of the highest-quality commercial laboratory assets in the world once complete,” says John Mooz, senior managing director at Hines, in the release. “We are excited to bring top-tier projects like Levit Green to other highly anticipated, growing markets.”

Boston and San Francisco have become major life science industry hubs, but there are several global cities on the rise that Hines will be targeting, including London, Boulder, Austin, Shanghai Salt Lake City, and Pittsburgh.

Hines’ investment thesis is based on a confluence of factors that are driving the demand within the global landscape for life sciences real estate that are outlined in the new Hines Perspective: “The Potential of Purpose-Built Properties” white paper.

Levit Green is a 270,000-square-foot Phase I lab building adjacent to the Texas Medical Center. Rendering courtesy of Hines

The new building features a waterfront, wharf environment. Rendering courtesy of Hines

Pivotal new waterfront science lab set to cast off in The Medical Center

LEVIT GREEN BLOOMS

The first step of a pivotal new Medical Center district has been revealed. International real estate firm Hines and partner 2ML Real Estate Interests have unveiled the first look at the initial building at Levit Green.

This new, 53-acre life science complex will sit adjacent to the Texas Medical Center. The five-story, 270,000-square-foot Phase I building is designated for life sciences; JLL has been selected as leasing representative for the project, per a press release.

Sitting on the first of several lakes that create Levit Green's oasis, Phase I boasts a sprawling boardwalk environment. Tenants will enjoy waterfront amenities including a 5,800-square foot fitness center and outdoor garden, 7,000-square-foot conference center, 3,500 square feet of café and restaurant space, and on-site parking.

Ground-floor plans include more than 25,000 square feet of lab incubator space, which will provide entrepreneurs and early-stage life science companies top-tier, strategically located laboratory and office space as well as networking opportunities, per a release.

As for the building itself, amenities include: 100-percent-redundant emergency power, enhanced structural vibration attenuation, and augmented mechanical systems. Work on Phase I is slated to begin in the second quarter of this year, with occupancy beginning in Q4.

The 53-acre Levit Green proposed site. Rendering courtesy of Hines

According to data, Houston produces more medical doctorates than any other MSA and generates more research doctorates in the key life science subject areas of biology and physical sciences (chemistry, physics, etc.) than San Francisco, San Diego, and Seattle. Thus, Levit Green promises to solve the real estate demands of arguably the nation's life science capital.

"Houston is quickly emerging as a top life science cluster city and has been able to do so without the purpose-built product established in other locations," said John Mooz, senior managing director at Hines, in a statement. "The Phase I project at Levit Green has been thoughtfully designed from the inside out to include features that are required of a top-tier research environment. We are excited to deliver the highest quality of building that will enable industry leaders to better conduct their critical research."

------

This article originally ran on CultureMap.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. Image courtesy of Hines

New development announced to rise alongside Houston's Texas Medical Center

now building

Two Houston-based commercial real estate companies — Hines Interests LP and 2ML Real Estate Interests Inc. — have teamed up to develop a 52-acre life-sciences-anchored, mixed-use project adjacent to the Texas Medical Center.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. In a June 15 release, the developers say Levit Green will sit "at the epicenter of Houston's biotech, corporate life sciences, and medical research hub."

Levit Green will be near the planned TMC³ biomedical research campus. The Hines-2ML project will be built at the northwest corner of Holcombe Boulevard and U.S. Highway 288 on an industrial site that was the headquarters of The Grocery Supply Co. Inc., the predecessor of 2ML.

Being built at a cost of $1.5 billion, the 1.5 million-square-foot, 36-acre TMC³ campus is set for completion in 2022.

"At 15.5 percent, Houston has one of the highest five-year growth rates in life sciences establishments in the United States. Impressive advancements in therapeutics, science, and innovation are driving demand for real estate," John Mooz, senior managing director of Hines, says in the release.

Privately held Hines is a real estate investor, developer, and manager whose portfolio comprises $133.3 billion in assets across 24 countries.

Because Levit Green remains in the master-planning phase, the developers aren't able to provide the project's square footage. They plan to break ground once design work for the initial buildings is finished. The developers decline to disclose a price tag for the project.

"Given the explosive growth and investment in innovation in the life science sector, there is an intense need for state-of-the-art facilities which enable the research required to bring these planned advances into being," Mooz tells InnovationMap in a statement. "As Houston is an ascending life science cluster city, which also includes the world's largest medical center, the need to create facilities that enhance research and development was, to us, obvious."

An initial parcel for Levit Green was purchased by Joe Levit, founder of The Grocers Supply Co., which grew into a major independent wholesaler of groceries in the U.S. and the largest supplier of Hispanic groceries in the U.S. The Levit family owns 2ML.

"Our family has deep roots in the neighborhood, and we believe this development will add tremendous value to the area and the Texas Medical Center," Max Levit, president of 2ML, says in the release.

The Levits entered the retail sector with the purchase of the Gerland's Inc. and Fiesta Mart Inc. grocery chains. In 2014, the family sold its wholesale business and the Grocers Supply name. The following year, the company sold Gerland's and Fiesta Mart.

In conjunction with the sale of the wholesale business and the brand, The Grocers Supply Co. changed its name to 2ML Real Estate Interests. The renamed company controls a portfolio of more than 5.2 million square feet of warehouses, shopping centers, supermarkets, and office buildings. The bulk of 2ML's portfolio is in the Houston area.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings